Answers are grounded in this paper and cite their sources.
Molecular dynamics analysis reveals GSM-1 binding interactions in gamma-secretase, suggesting pathways for new drug designs.
γ-Secretase (GS) is a key therapeutic target in Alzheimer's disease because it catalyzes amyloid-β production. To reduce toxic amyloid-β species, several γ-secretase modulators (GSMs) have been developed. Among these, GSM-1, a piperidine carboxylic acid-based modulator, has shown potent activity in preclinical studies; however, its binding site and molecular mechanism remain unclear. Here, a molecular dynamics protocol inspired by the Wrap-'N'-Shake approach was used to investigate how the axial and equatorial conformations of the piperidine nitrogen in GSM-1 interact with GS's presenilin subunit. Both conformations formed stable interactions with presenilin TM1 and TM5. The carboxylate group established persistent interactions with R220 in TM5, while the trifluoromethylphenyl group engaged residues K76, K80, V87, and L91 in TM1. These findings provide the first model of GSM-1 engagement with GS, identify the key GSM-1 chemical groups involved in recognition, and establish a mechanistic foundation for the rational design of next-generation GSM analogs.
No takes yet. Share an insight, caveat, or question.
Santiago et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: